BioSpace News Archive

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced it has presented data from an ongoing Phase 1/2 clinical trial entitled “A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions”

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.53 per share, payable on January 29, 2020 to shareholders of record of Quest Diagnostics common stock on January 14, 2020.

Company adds experienced medical executive to management team and leading nephrologists to Medical Advisory Board

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score [CPS] ≥1)

CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief Executive Officer, Dan Menichella, will present a corporate overview at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 3, 2019.

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced that the American College of Rheumatology (ACR) has included the Vectra® test in its list of recommended disease activity measures for patients with rheumatoid arthritis (RA)

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced publication of results from the Phase 3 open-label safety study (ATHENA) for IV oliceridine in The Journal of Pain Research.

Emerald Health Therapeutics, Inc. responded to inaccurate allegations made by Village Farms International, Inc. in connection with their 50/50 joint venture, Pure Sunfarms Corp., and updated the market on certain related matters.

Global Cord Blood Corporation (NYSE: CO) (the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today commented on a new regulation related to companies in possession of human DNA information relating to the PRC

mRNA Day is being celebrated in the City of San Diego following a proclamation in honor of Maravai LifeSciences and the grand opening of its new headquarters in the City.